Device-detektiertes Vorhofflimmern – was nun?: Executive Summary des DGK-Positionspapiers

Tobias Tönnis; Nina Becher; Ralf Birkemeyer; David Duncker; Lars Eckardt; Klaus Gröschel; Dominik Linz; Christian Meyer; Florian Straube; Arian Sultan; Rolf Wachter; Maura Zylla; Paulus Kirchhof

doi:10.1007/s00399-025-01112-7

Device-detektiertes Vorhofflimmern – was nun? Executive Summary des DGK-Positionspapiers

Translated title of the contribution: What to do with device-detected atrial fibrillation?: Executive summary of the position paper of the German Society of Cardiology

Tobias Tönnis^*
, Nina Becher
, Ralf Birkemeyer
, David Duncker
, Lars Eckardt
, Klaus Gröschel
, Dominik Linz
, Christian Meyer
, Florian Straube
, Arian Sultan
, Rolf Wachter
, Maura Zylla
, Paulus Kirchhof

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Device-detected atrial fibrillation (DDAF), like clinical atrial fibrillation (AF), is also associated with an increased risk of thromboembolic events, although the risk appears to be significantly lower. The efficacy and safety of oral anticoagulation in DDAF were investigated in two large randomized trials (NOAH-AFNET 6 and ARTESIA [13, 19]). They showed a low rate of ischemic strokes without anticoagulation (about 1% per year). This risk can still be reduced by therapeutic anticoagulation, but the risk of severe bleeding increases. In the recently published position paper [36] of the German Society of Cardiology, the current study situation was presented and expert recommendations were given on how to deal with DDAF.

Translated title of the contribution	What to do with device-detected atrial fibrillation?: Executive summary of the position paper of the German Society of Cardiology
Original language	German
Pages (from-to)	49-56
Number of pages	8
Journal	Herzschrittmachertherapie und Elektrophysiologie
Volume	37
Issue number	1
Early online date	1 Jan 2025
DOIs	https://doi.org/10.1007/s00399-025-01112-7
Publication status	Published - Mar 2026

Keywords

Anticoagulation
Atrial fibrillation
Heart and brain
ICD
Pacemaker

Access to Document

10.1007/s00399-025-01112-7Licence: CC BY

Cite this

Tönnis, T., Becher, N., Birkemeyer, R., Duncker, D., Eckardt, L., Gröschel, K., Linz, D., Meyer, C., Straube, F., Sultan, A., Wachter, R., Zylla, M., & Kirchhof, P. (2026). Device-detektiertes Vorhofflimmern – was nun? Executive Summary des DGK-Positionspapiers. Herzschrittmachertherapie und Elektrophysiologie, 37(1), 49-56. https://doi.org/10.1007/s00399-025-01112-7

@article{179d08c32f4c4ba1aedb41dd9dbebedc,

title = "Device-detektiertes Vorhofflimmern – was nun?: Executive Summary des DGK-Positionspapiers",

abstract = "Device-detected atrial fibrillation (DDAF), like clinical atrial fibrillation (AF), is also associated with an increased risk of thromboembolic events, although the risk appears to be significantly lower. The efficacy and safety of oral anticoagulation in DDAF were investigated in two large randomized trials (NOAH-AFNET 6 and ARTESIA [13, 19]). They showed a low rate of ischemic strokes without anticoagulation (about 1\% per year). This risk can still be reduced by therapeutic anticoagulation, but the risk of severe bleeding increases. In the recently published position paper [36] of the German Society of Cardiology, the current study situation was presented and expert recommendations were given on how to deal with DDAF.",

keywords = "Anticoagulation, Atrial fibrillation, Heart and brain, ICD, Pacemaker",

author = "Tobias T{\"o}nnis and Nina Becher and Ralf Birkemeyer and David Duncker and Lars Eckardt and Klaus Gr{\"o}schel and Dominik Linz and Christian Meyer and Florian Straube and Arian Sultan and Rolf Wachter and Maura Zylla and Paulus Kirchhof",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2026",

month = mar,

doi = "10.1007/s00399-025-01112-7",

language = "German",

volume = "37",

pages = "49--56",

journal = "Herzschrittmachertherapie und Elektrophysiologie",

issn = "0938-7412",

publisher = "Springer Medizin",

number = "1",

}

Tönnis, T, Becher, N, Birkemeyer, R, Duncker, D, Eckardt, L, Gröschel, K, Linz, D, Meyer, C, Straube, F, Sultan, A, Wachter, R, Zylla, M & Kirchhof, P 2026, 'Device-detektiertes Vorhofflimmern – was nun? Executive Summary des DGK-Positionspapiers', Herzschrittmachertherapie und Elektrophysiologie, vol. 37, no. 1, pp. 49-56. https://doi.org/10.1007/s00399-025-01112-7

TY - JOUR

T1 - Device-detektiertes Vorhofflimmern – was nun?

T2 - Executive Summary des DGK-Positionspapiers

AU - Tönnis, Tobias

AU - Becher, Nina

AU - Birkemeyer, Ralf

AU - Duncker, David

AU - Eckardt, Lars

AU - Gröschel, Klaus

AU - Linz, Dominik

AU - Meyer, Christian

AU - Straube, Florian

AU - Sultan, Arian

AU - Wachter, Rolf

AU - Zylla, Maura

AU - Kirchhof, Paulus

PY - 2026/3

Y1 - 2026/3

N2 - Device-detected atrial fibrillation (DDAF), like clinical atrial fibrillation (AF), is also associated with an increased risk of thromboembolic events, although the risk appears to be significantly lower. The efficacy and safety of oral anticoagulation in DDAF were investigated in two large randomized trials (NOAH-AFNET 6 and ARTESIA [13, 19]). They showed a low rate of ischemic strokes without anticoagulation (about 1% per year). This risk can still be reduced by therapeutic anticoagulation, but the risk of severe bleeding increases. In the recently published position paper [36] of the German Society of Cardiology, the current study situation was presented and expert recommendations were given on how to deal with DDAF.

AB - Device-detected atrial fibrillation (DDAF), like clinical atrial fibrillation (AF), is also associated with an increased risk of thromboembolic events, although the risk appears to be significantly lower. The efficacy and safety of oral anticoagulation in DDAF were investigated in two large randomized trials (NOAH-AFNET 6 and ARTESIA [13, 19]). They showed a low rate of ischemic strokes without anticoagulation (about 1% per year). This risk can still be reduced by therapeutic anticoagulation, but the risk of severe bleeding increases. In the recently published position paper [36] of the German Society of Cardiology, the current study situation was presented and expert recommendations were given on how to deal with DDAF.

KW - Anticoagulation

KW - Atrial fibrillation

KW - Heart and brain

KW - ICD

KW - Pacemaker

U2 - 10.1007/s00399-025-01112-7

DO - 10.1007/s00399-025-01112-7

M3 - (Systematic) Review article

SN - 0938-7412

VL - 37

SP - 49

EP - 56

JO - Herzschrittmachertherapie und Elektrophysiologie

JF - Herzschrittmachertherapie und Elektrophysiologie

IS - 1

ER -

Device-detektiertes Vorhofflimmern – was nun? Executive Summary des DGK-Positionspapiers

Abstract

Keywords

Access to Document

Fingerprint

Cite this